Target Name: PARP15
NCBI ID: G165631
Review Report on PARP15 Target / Biomarker Content of Review Report on PARP15 Target / Biomarker
PARP15
Other Name(s): PAR15_HUMAN | OTTHUMP00000215802 | B-aggressive lymphoma protein 3 | PARP15 variant 2 | poly(ADP-ribose) polymerase family member 15 | FLJ40597 | Protein mono-ADP-ribosyltransferase PARP15 (isoform 1) | Poly(ADP-ribose) polymerase family member 15, transcript variant 2 | Poly (ADP-ribose) polymerase-15 (PARP-15) | MGC126750 | pART7 | poly [ADP-ribose] polymerase 15 | PART7 | Protein mono-ADP-ribosyltransferase PARP15 (isoform 2) | OTTHUMP00000215684 | ARTD7 | ADP-ribosyltransferase diphtheria toxin-like 7 | B-aggressive lymphoma 3 | BAL3 | PARP15 variant 1 | PARP-15 | Protein mono-ADP-ribosyltransferase PARP15 | OTTHUMP00000215801 | OTTHUMP00000215685 | Poly(ADP-ribose) polymerase family member 15, transcript variant 1 | FLJ40196 | MGC126752

PARP-15: A Potential Drug Target and Biomarker

Parp15 is a protein that is expressed in various tissues of the body, including the brain, spleen, and gastrointestinal tract. It is a key regulator of the DNA damage response pathway, which is responsible for repairing damaged DNA in response to environmental stressors, such as radiation and chemicals. Activated DNA- Damage-Inducible Gene (AD-IN) transcription factors, which include Parp15, play a crucial role in this process.

PARP-15 functions as a negative regulator of the transcription factor APC1, which is responsible for repairing DNA double-strand breaks in the germline. When DNA damage occurs, Parp15 helps to prevent APC1 from binding to the damaged site and initiating the DNA-damage response. This protein does this by forming a complex with the transcription factor MyD88, which inhibits the recruitment of MyD88 to the damaged site.

PARP-15 is also involved in the regulation of apoptosis, which is a natural response of cells to DNA damage. When DNA is damaged, the cell's immune response is activated, and the cell undergoes apoptosis in order to eliminate the damaged DNA before it spreads the mutation to other cells. Parp15 is required for the execution of this process, as it helps to regulate the transfer of DNA damage from the damaged cell to the surrounding cells.

In addition to its role in the DNA damage response pathway, PARP-15 is also a potential drug target. The ability of this protein to regulate the DNA damage response pathway makes it an attractive target for small molecules that can inhibit the activity of APC1 and MyD88, which are involved in the regulation of DNA damage. This would result in a reduction in the number of cells that are subject to DNA damage, which could have potential therapeutic applications.

PARP-15 is also a biomarker for several diseases, including cancer. The number of cells that are affected by DNA damage is a key indicator of the level of stress that cells are subjected to. This is because when cells are exposed to stressors, they are more likely to experience DNA damage, which can lead to the development of cancer. Therefore, measuring the level of DNA damage in cells can be a useful diagnostic tool for cancer detection.

In conclusion, PARP-15 is a protein that is involved in the regulation of the DNA damage response pathway. Its role in this pathway makes it an attractive target for small molecules that can inhibit the activity of APC1 and MyD88. In addition, PARP-15 is also a biomarker for several diseases, including cancer. Further research is needed to fully understand the role of this protein in the regulation of DNA damage and its potential as a drug target.

Protein Name: Poly(ADP-ribose) Polymerase Family Member 15

Functions: Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins (PubMed:16061477, PubMed:25043379, PubMed:25635049). Acts as a negative regulator of transcription (PubMed:16061477)

The "PARP15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARP15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

PARP16 | PARP2 | PARP3 | PARP4 | PARP6 | PARP8 | PARP9 | PARPBP | PARS2 | PART1 | PARTICL | PARVA | PARVB | PARVG | Parvovirus initiator complex | PASD1 | PASK | Patatin-like phospholipase domain-containing protein | PATE1 | PATE2 | PATE3 | PATE4 | PATJ | PATL1 | PATL2 | PATZ1 | PAUPAR | PAWR | PAX1 | PAX2 | PAX3 | PAX4 | PAX5 | PAX6 | PAX6-AS1 | PAX7 | PAX8 | PAX8-AS1 | PAX9 | PAXBP1 | PAXBP1-AS1 | PAXIP1 | PAXIP1-AS2 | PAXIP1-DT | PAXX | PBDC1 | PBK | PBLD | PBOV1 | PBRM1 | PBX1 | PBX2 | PBX3 | PBX3-DT | PBX4 | PBXIP1 | PC | PCA3 | PCAF complex | PCARE | PCAT1 | PCAT14 | PCAT18 | PCAT19 | PCAT2 | PCAT29 | PCAT4 | PCAT5 | PCAT6 | PCAT7 | PCBD1 | PCBD2 | PCBP1 | PCBP1-AS1 | PCBP2 | PCBP2-OT1 | PCBP2P2 | PCBP3 | PCBP3-AS1 | PCBP4 | PCCA | PCCA-DT | PCCB | PCDH1 | PCDH10 | PCDH11X | PCDH11Y | PCDH12 | PCDH15 | PCDH17 | PCDH18 | PCDH19 | PCDH20 | PCDH7 | PCDH8 | PCDH9 | PCDH9-AS3 | PCDH9-AS4 | PCDHA1 | PCDHA10